Osaki A - Search Results

1

The prognostic significance of p53, p21 (Waf1/Cip1), and cyclin D1 protein expression in esophageal cancer patients.

Hirai T, Kuwahara M, Yoshida K, Osaki A, Toge T. Hirai T, et al. Among authors: osaki a. Anticancer Res. 1999 Sep-Oct;19(5C):4587-91. Anticancer Res. 1999. PMID: 10650815

2

Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients.

Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Osaki A, et al. Am J Surg. 1992 Oct;164(4):323-6. doi: 10.1016/s0002-9610(05)80897-9. Am J Surg. 1992. PMID: 1357997

3

[Prognostic significance of expression of c-ERBB-2 oncoprotein in breast cancer patients].

Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Osaki A, et al. Gan To Kagaku Ryoho. 1991 Jun;18(7):1181-5. Gan To Kagaku Ryoho. 1991. PMID: 1675844 Japanese.

4

Epidermal growth factor receptor expression as a prognostic indicator in breast cancer.

Toi M, Osaki A, Yamada H, Toge T. Toi M, et al. Among authors: osaki a. Eur J Cancer. 1991;27(8):977-80. doi: 10.1016/0277-5379(91)90262-c. Eur J Cancer. 1991. PMID: 1832907

5

[The expression of NCC-ST-439, a tumor marker, in human breast cancer patients].

Miyahara E, Toi M, Wada T, Yamada H, Osaki A, Yanagawa E, Toge T. Miyahara E, et al. Among authors: osaki a. Gan No Rinsho. 1990 Sep;36(11):2023-6. Gan No Rinsho. 1990. PMID: 2232168 Japanese.

6

Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer.

Toi M, Nakamura T, Mukaida H, Wada T, Osaki A, Yamada H, Toge T, Niimoto M, Hattori T. Toi M, et al. Among authors: osaki a. Cancer. 1990 May 1;65(9):1980-4. doi: 10.1002/1097-0142(19900501)65:9<1980::aid-cncr2820650917>3.0.co;2-u. Cancer. 1990. PMID: 2372767

7

Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study.

Toi M, Tominaga T, Osaki A, Toge T. Toi M, et al. Among authors: osaki a. Breast Cancer Res Treat. 1994 Jan;29(1):51-8. doi: 10.1007/BF00666181. Breast Cancer Res Treat. 1994. PMID: 7912567 Clinical Trial.

8

Primary squamous cell carcinoma of the breast after cured Hodgkin's disease.

Kuroi K, Osaki A, Yamada H, Toi M, Toge T, Takimoto Y, Kuramoto A, Arihiro K, Inai K. Kuroi K, et al. Among authors: osaki a. Surg Today. 1993;23(1):81-4. doi: 10.1007/BF00309006. Surg Today. 1993. PMID: 8461611

9

A Combination Therapy with Mitomycin C, Etoposide, Doxifluridine and Medroxyprogesterone Acetate as Second Line Therapy for Advanced Breast Cancer Refractory to Combination Chemotherapy of Cyclo-phoshamide, Doxorubicin and 5-Fluorouracil.

Kuroi K, Osaki A, Kawami H, Murakami S, Toge T. Kuroi K, et al. Among authors: osaki a. Breast Cancer. 1997 Jul 31;4(2):115-119. doi: 10.1007/BF02967064. Breast Cancer. 1997. PMID: 11091585

10

A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action.

Kim R, Osaki A, Tanabe K, Kojima J, Toge T. Kim R, et al. Among authors: osaki a. Oncol Rep. 2001 May-Jun;8(3):597-603. doi: 10.3892/or.8.3.597. Oncol Rep. 2001. PMID: 11295087 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

183 results

Search Page

Filters